Anzeige
Mehr »
Mittwoch, 06.08.2025 - Börsentäglich über 12.000 News
Warum Guardian Metal die Pentagon-gestützte Antwort auf Chinas Dominanz ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AG6H | ISIN: US45826J1051 | Ticker-Symbol: 38I
Tradegate
05.08.25 | 21:44
10,020 Euro
-4,39 % -0,460
1-Jahres-Chart
INTELLIA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
INTELLIA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,96610,07005.08.
9,96610,07005.08.

Aktuelle News zur INTELLIA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
INTELLIA THERAPEUTICS Aktie jetzt für 0€ handeln
FrIntellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)110CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies...
► Artikel lesen
07.07.Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)364CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies...
► Artikel lesen
07.07.Intellia Gains 29.8% in a Month: How Should You Play the Stock?55
25.06.CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?92
23.06.Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress40
17.06.Intellia's three-year HAE treatment data shows durability, Citizens JMP says76
16.06.Assessing Intellia Therapeutics: Insights From 9 Financial Analysts65
16.06.Intellia's HAE gene therapy shows 98% attack reduction in three-year data32
15.06.Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy ...276With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median...
► Artikel lesen
12.06.Intellia Therapeutics, Inc. - 8-K, Current Report6
11.06.Intellia Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans8
05.06.Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)211CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies...
► Artikel lesen
03.06.Canaccord Genuity lowers Intellia stock price target to $5449
31.05.Cathie Wood's ARK buys Intellia, 10x Genomics, sells Tesla stock191
29.05.Intellia filing spurs safety concerns over CRISPR drug47
29.05.Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course31
29.05.Intellia's stock sinks on gene therapy patient's raised enzyme levels, but analysts keep faith42
29.05.Intellia stock holds $45 target despite AE concerns50
29.05.Cantor maintains Intellia stock at $65 target despite trial concern22
29.05.Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews17
Weiter >>
80 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,1,17